Therapeutic use of anti-CGRP monoclonal antibodies is one of the most important recent advances in migraine treatment. But what do they target, and how do they work? Prof. Uwe Reuter provides an in-depth overview of this new advance in migraine treatment, and discusses European Headache Federation recommendations for their use.